Advancing standards of care for Pulmonary Embolism
Each year nearly one million patients in the U.S. and Europe are affected by Pulmonary Embolism (PE), a blood clot causing a blockage in one or more pulmonary arteries within the lungs.
In intermediate-risk or high-risk cases of PE, the blockage may lead to a strain on the heart’s ability to pump blood through the lungs and can be fatal. The current standard of care for PE is anticoagulation, though there are disparate guidelines to direct safe and effective treatment of patients with intermediate-high-risk PE.
Boston Scientific aims to make ultrasound-accelerated thrombolysis the new standard of care for patients with intermediate-high-risk PE. Minimally invasive, this 15-minute procedure requires lower lytic doses, limits bleeding, and has proven patient outcomes.1
Pulmonary embolism (PE) is a significant cause of death for hospitalised patients– directly causing or contributing to 15% of hospital deaths.2
Learn more about the symptoms of Pulmonary Embolism >
Pulmonary Embolism can be immediately fatal, but studies show that mortality can be reduced from 30% to <5% with appropriate diagnosis and treatment.1,3
ESC Guidelines provide a roadmap for diagnosis. Learn more >
Every 60 seconds someone is diagnosed with Pulmonary Embolism.
It takes a united front to take action against this complex disease.
Watch the full video here >
The use of interventional treatment in PE is backed by patient outcomes and long-term clinical evidence. Recent studies like HI-PEITHO and KNOCOUT will help advance standards of care for PE patients.
Learn to diagnose and treat Pulmonary Embolism
Get the details about the BSC learning program on Pulmonary Embolism >